The company has acquired “a virtual library of over a billion molecules”, which should give the company a boost when it starts new discovery programmes.
According to Dr Clive Dix, the chief executive officer of C4X, the newly acquired software is “all about optimising those molecules that we find by using our other technologies”.
Dr Dix told Proactive Investors: “Everything we do is aimed at reducing the time and the cost of getting to the clinical trial and then … with the molecules we have being of higher quality, they’ll be more likely to be successful in the trials.”
The company will be starting new projects on a regular basis and when the time is right will decide on a case-by-case basis whether to bring in a partner or take the drugs to clinical trial independently.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.